Avenue Therapeutics, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Cover
- Document and Entity Information
Financial Statements
Notes to Financial Statements
Accounting Policies
- Significant Accounting Policies (Policies)
Notes Tables
Notes Details

License/Supplier Agreements (Details)

v3.23.1

License/Supplier Agreements (Details) - USD ($) $ in Millions			1 Months Ended
	Oct. 29, 2018	Feb. 17, 2015	Dec. 31, 2019	Jun. 17, 2015
Term of agreement		5 years
Revogenex License
Contractual Obligation, Maximum Future Payments				$ 3.0
Baergic Licenses
Development milestone payments			$ 81.5
Commercial and sales based milestone payments			$ 151.0
Baergic Licenses \| AZ
Percentage of equity fee			20.00%
Baergic Licenses \| CCHMC
Percentage of equity fee			5.00%
Upfront Payment \| Baergic Licenses \| AZ
Payments to acquire in process research and development			$ 3.0
Upfront Payment \| Baergic Licenses \| CCHMC
Payments to acquire in process research and development			0.2
IV Tramadol \| Fortress Biotech Inc \| Upfront Payment
Payments to acquire in process research and development				2.0
IV Tramadol \| Fortress Biotech Inc \| Additional Payment
Payments to acquire in process research and development				$ 1.0
Polpharma
Payments to acquire in process research and development	$ 2.0
New Drug Application \| Revogenex License
Payments to acquire in process research and development			$ 1.0

- Definition

Amount of required maximum commercial under contractual obligation.

+ References

No definition available.

+ Details

Name:	atxi_ContractualObligationCommercialExpense
Namespace Prefix:	atxi_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of required maximum development under contractual obligation.

+ References

No definition available.

+ Details

Name:	atxi_ContractualObligationDevelopmentExpense
Namespace Prefix:	atxi_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of required maximum future payments under contractual obligation.

+ References

No definition available.

+ Details

Name:	atxi_ContractualObligationMaximumFuturePayments
Namespace Prefix:	atxi_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The percentage of equity fee.

+ References

No definition available.

+ Details

Name:	atxi_PercentageOfEquityFee
Namespace Prefix:	atxi_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

The term of agreement.

+ References

No definition available.

+ Details

Name:	atxi_TermOfAgreement
Namespace Prefix:	atxi_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585

+ Details

Name:	us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=atxi_RevogenexLicenseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=atxi_BaergicLicensesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=atxi_AzMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=atxi_CchmcMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_GuaranteeObligationsByNatureAxis=atxi_UpfrontPaymentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=atxi_IvTramadolMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dei_LegalEntityAxis=atxi_FortressBiotechIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_GuaranteeObligationsByNatureAxis=atxi_AdditionalPaymentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=atxi_PolpharmaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=atxi_NewDrugApplicationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: